You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on minimal residual disease testing.
In its IPO prospectus, the company shared plans to broaden the use of its methylation technology from cancer screening to diagnostics and residual disease monitoring.
The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.
The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.
The Signatera test is optimized for molecular residual disease (MRD) assessment and for monitoring treatment in cancer patients.
The company has been authorized by the state of New Jersey to provide sequencing-based cancer detection and surveillance using patient-specific ctDNA assays.
The company was able to ramp up recruitment for its pivotal ECLIPSE trial after hurdles caused a falloff during the earlier months of the COVID-19 pandemic.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases.
The technique, called INVAR, applies error-suppression methods and signal enrichment to analyze hundreds of loci to detect circulating tumor DNA in blood samples.
ArcherDX said the firms aim to apply minimal residual disease monitoring in clinical-trial protocols and for future therapy optimization.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.